Skip to content
TrialScanner

NCT00602030

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Phase 1/Phase 2CompletedSNDXLead

Registry record

Lead sponsor
Syndax Pharmaceuticals
Conditions
Non-Small-Cell Lung Carcinoma; Carcinoma, Non-Small Cell Lung
Primary completion
Feb 4, 2010Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00602030 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00602030: Study to Evaluate Erlotinib... | TrialScanner